Phase III Study, CONTACT-02: A Phase III, Randomized, Open-Label, Controlled Study of Cabozantinib XL 184 in Combination with Atezolizumab vs Second Novel Hormonal Therapy NHT in Subjects with Metastatic Castration-Resistant Prostate Cancer

Brief Summary

Type:
Prostate

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT04446117

Study #:
STUDY00147114

Start Date:
Mar 08, 2022

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT04446117

View Complete Trial Details & Eligibility at ClinicalTrials.gov